Literature DB >> 23474287

Mechanisms of regulatory T cell counter-regulation by innate immunity.

Heidi Yeh1, Daniel J Moore, James F Markmann, James I Kim.   

Abstract

One of the most significant advances in the field of immunology in the last decade is delineation of the pivotal role of regulatory T cells (Tregs) in the maintenance of self-tolerance. While Tregs are just now being applied therapeutically in early phase clinical trials, data gleaned from basic and translational studies to-date suggest enormous potential to intervene in human disease. Data from our work and the work of others suggest that the innate immune system plays an important role in the differentiation and function of Tregs, largely through the production of cytokines but also through expression of cell surface ligands. These molecules are expressed differentially depending on whether the stimulus includes trauma, ischemia/necrosis, and microbial infection, and have opposing effects on Tregs, in contrast to those associated with dendritic cell maturation and somatic cell apoptosis, which promote Treg differentiation and function. We refer to the former process as Treg counter-regulation. Since the transplantation procedure involves surgical trauma, organ ischemia, and exposure to environmental microbes, Treg counter-regulation represents a key area of intervention to improve strategies for promoting allograft tolerance.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23474287      PMCID: PMC3637936          DOI: 10.1016/j.trre.2013.02.001

Source DB:  PubMed          Journal:  Transplant Rev (Orlando)        ISSN: 0955-470X            Impact factor:   3.943


  78 in total

1.  Prolonged survival of allogeneic islet grafts in NOD mice treated with a combination of anti-CD45RB and anti-CD154 antibodies.

Authors:  R D Molano; T Berney; A Pileggi; C Ricordi; L Burkly; D Rothstein; G Basadonna; L Inverardi
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

2.  Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells.

Authors:  Sabine Dominitzki; Massimo C Fantini; Clemens Neufert; Alexei Nikolaev; Peter R Galle; Jürgen Scheller; Giovanni Monteleone; Stefan Rose-John; Markus F Neurath; Christoph Becker
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

3.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.

Authors:  Luke M Williams; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2007-01-14       Impact factor: 25.606

4.  Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells.

Authors:  Todd S Davidson; Richard J DiPaolo; John Andersson; Ethan M Shevach
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance.

Authors:  Thomas B Thornley; Nancy E Phillips; Britte C Beaudette-Zlatanova; Thomas G Markees; Kapil Bahl; Michael A Brehm; Leonard D Shultz; Evelyn A Kurt-Jones; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

6.  GITR ligation blocks allograft protection by induced CD25+CD4+ regulatory T cells without enhancing effector T-cell function.

Authors:  A Bushell; K Wood
Journal:  Am J Transplant       Date:  2007-04       Impact factor: 8.086

7.  Cutting Edge: Immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-beta-dependent manner.

Authors:  Roopali Gandhi; David E Anderson; Howard L Weiner
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

8.  IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.

Authors:  Mika Nishihara; Hideki Ogura; Naoko Ueda; Mineko Tsuruoka; Chika Kitabayashi; Fumio Tsuji; Hiroyuki Aono; Katsuhiko Ishihara; Eric Huseby; Ulrich A K Betz; Masaaki Murakami; Toshio Hirano
Journal:  Int Immunol       Date:  2007-05-09       Impact factor: 4.823

9.  IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

Authors:  Thomas Korn; Estelle Bettelli; Wenda Gao; Amit Awasthi; Anneli Jäger; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

10.  Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.

Authors:  Ursula Grohmann; Claudia Volpi; Francesca Fallarino; Silvia Bozza; Roberta Bianchi; Carmine Vacca; Ciriana Orabona; Maria L Belladonna; Emira Ayroldi; Giuseppe Nocentini; Louis Boon; Francesco Bistoni; Maria C Fioretti; Luigina Romani; Carlo Riccardi; Paolo Puccetti
Journal:  Nat Med       Date:  2007-04-08       Impact factor: 53.440

View more
  4 in total

1.  Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks.

Authors:  Mohamed B Ezzelarab; Angus W Thomson
Journal:  Curr Transplant Rep       Date:  2016-10-25

2.  Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.

Authors:  M B Ezzelarab; H Zhang; H Guo; L Lu; A F Zahorchak; R W Wiseman; M A Nalesnik; J K Bhama; D K C Cooper; A W Thomson
Journal:  Am J Transplant       Date:  2016-03-17       Impact factor: 8.086

3.  Low expression and hypermethylation of FOXP3 in regulatory T cells are associated with asthma in children.

Authors:  Xiaohua Zhu; Qiang Chen; Zhiqiang Liu; Daya Luo; Lan Li; Ying Zhong
Journal:  Exp Ther Med       Date:  2020-01-10       Impact factor: 2.447

Review 4.  Crosstalk between the CBM complex/NF-κB and MAPK/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment.

Authors:  Tongbing Qi; Ying Luo; Weitong Cui; Yue Zhou; Xuan Ma; Dongming Wang; Xuewen Tian; Qinglu Wang
Journal:  Front Cell Dev Biol       Date:  2022-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.